GTC Biotherapeutics (fka GTCB)

[CapraVacca]

"GTC is making significant progress, both in the near-term with ATryn(R), our recombinant form of human antithrombin, and strategically with the development of portfolios of recombinant plasma proteins and monoclonal antibodies, including follow-on biologics," stated Geoffrey F. Cox, Ph.D., GTC's Chairman and CEO. "We are confident in our ability to reach significant milestones in our clinical and commercialization programs and will consider actions as appropriate to address compliance with the continued listing requirements of the Nasdaq Global Market."

http://www.pharmalive.com/News/index.cfm?articleid=507026&categoryid=36%2C61

Grtz CV